Limited coverage drugs – solifenacin
Last updated on October 11, 2022
|
Generic name |
solifenacin (eligible generic versions only) |
|---|---|
|
Strength |
5 mg, 10 mg |
| Form |
tablet |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of patients with overactive bladder syndrome1 who have developed severe intolerance2 to immediate-release oxybutynin requiring discontinuation of oxybutynin. |
Indefinite |
Notes
- Overactive bladder syndrome is defined as urgency with or without urgency incontinence, usually accompanied by urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology.
- Specific details of the severe intolerance must be provided.
Practitioner exemptions
- None
Special notes
- Solifenacin for stress incontinence is not eligible for coverage.
- Behavioral management protocols (e.g. bladder training, bladder control strategies, pelvic floor muscle training, fluid management) OR referral to a continence bladder care program should be considered as effective primary treatments for overactive bladder syndrome.